Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Research patients enrolled are those patients with relapsed or refractory CD123+ acute leukemia (Acute Myeloid Leukemia/ acute lymphoblastic leukemia );~2. Relapsed: is defined as patients that had a first complete remission (CR) before developing recurrent disease (increased bone marrow blasts);~3. Refractory: is defined as patients that have not achieved a first CR after 2 cycles of induction chemotherapy; for patients with leukemia evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy;~4. Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis; CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry; cytogenetics, flow cytometry, and molecular studies (such as FMS-like tyrosine kinase-3 \[FLT-3\] status) will be obtained as per standard practice;~5. Karnofsky performance status score \>= 70;~6. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately;~7. Calculated creatinine clearance (absolute value) of \>= 50 mL/minute or creatinine \< 2.0 mg/dl or \< 2 times upper limit of normal for the research participant's age group;~8. Serum bilirubin =\< 3.0 mg/dL;~9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 5 times the institutional upper limits of normal;~10. Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) \>= 50%;~11. Diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) \> 45% predicted;~12. Research participants' last dose of prior chemotherapy or radiation must be \>= 2 weeks before leukapheresis;~13. If a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for graft versus host disease (GVHD) for at least 2 weeks before undergoing leukapheresis;~14. Negative serum or urine pregnancy test;~15. All research participants must have the ability to understand and willingness to sign a written informed consent or age appropriate assent for pediatric patients.~Exclusion Criteria:~1. Acute Promyelocytic Leukemia, t(15,17) (q22;q12);~2. Pregnant and lactating women;~3. Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection, or poorly controlled infection;~4. History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab~5. Dependence on corticosteroids (5mg/day prednisone more than 2 weeks);~6. A known hypersensitivity to any of the test materials or related compounds;~7. Presence of active and clinically relevant Central Nervous System (CNS) disorder;~8. Undergone prior allogeneic stem cell transplant, GVHD occurred within 6 months, requiring immunosuppressive therapy;~9. Active autoimmune disease, such as psoriasis and rheumatoid arthritis;~10. Other situations the clinicians think not eligible for participation in the research.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti-CD123 CAR-T treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).